ライフサイエンスコーパス: treatment

1 development of more effective individualized treatment.

2 ng therapy for cancer patients receiving Dox treatment.

3 refore, is not compatible with point-of-care treatment.

4 n ophthalmologist for further evaluation and treatment.

5 nic for treatment and did not reduce time to treatment.

6 ents who received at least one dose of study treatment.

7 hile infusions were analyzed without any pre-treatment.

8 ired T-cell development and is fatal without treatment.

9 cataract surgery, and assigned AREDS2 study treatment.

10 mental N deposition, relative to the ambient treatment.

11 rvival (OS) in 20 or more patients following treatment.

12 treatment, and there is a lack of effective treatment.

13 ctioning following 12 weeks of antipsychotic treatment.

14 nt and reemerged in the blood 24 weeks after treatment.

15 ned to open or placebo-controlled citalopram treatment.

16 s that depleting B cells could be useful for treatment.

17 ance of tumor-derived microRNA rapidly after treatment.

18 ide an important reference for diagnosis and treatment.

19 and specific AEP inhibitor useful for cancer treatment.

20 ets, which are oxidized in a subsequent heat treatment.

21 in the serum of AOM rats increased after KJT treatment.

22 nded in the setting of systemic isotretinoin treatment.

23 y markers were measured before and after FBX treatment.

24 ected therapeutic adjuvants for tuberculosis treatment.

25 ) were suspected to be related to everolimus treatment.

26 n of custirsen to cabazitaxel and prednisone treatment.

27 r were increased by proinflammatory thrombin treatment.

28 Th2 subset (CCR3(+)) was increased after DMF treatment.

29 d those reported to have started second-line treatment.

30 lture is a predictor of clinical response to treatment.

31 Tuberculosis relapse is a barrier to shorter treatment.

32 ampering the search for novel biomarkers and treatments.

33 eplication is important for developing novel treatments.

34 There are no proven treatments.

35 red benign and without guideline-recommended treatments.

36 e lowest proportion of individuals who chose treatment (311 [57.7%] and 328 [60.9%]).

37 ng the 3614 patients, regardless of assigned treatment, 33.3% had a deterioration in QoL, 9.2% had no

38 ociated with a high reclassification rate of treatment (38%).

39 posure to high temperature short time (HTST) treatment, a commonly used viral clearance upstream stra

40 Three patients received treatment activities of 5.1-7.5 GBq.

41 Offspring of elevated pCO2-treatment adults were significantly more vulnerable to a

42 opecia areata (AA) is important not only for treatment advancements, but also for possibly identifyin

43 important in order to optimize diagnosis and treatment algorithms.

44 nts (71%) who completed the 24 weeks of X-82 treatment, all except 1 maintained or improved their vis

45 compared with opioid taper or psychological treatments alone?

46 IS treatment alters innate antimicrobial defenses and disru

47 vention required people to attend clinic for treatment and did not reduce time to treatment.

48 topped therapy after at least 3 years of TKI treatment and in molecular response 4.5 (MR4.5) with und

49 Patients who completed 6 months of treatment and remained seizure-free entered a 6-month ma

50 t symptom not requiring immediate antibiotic treatment and with no history of chronic pulmonary disea

51 become uncoupled, including pharmacological treatments and disease models.

52 tional platform suitable for on-chip thermal treatments and on-chip detection of biomolecules.

53 the peripheral aspect within 1 to 2 weeks of treatment, and clinical resolution of lesions within 2 m

54 ital stay, improving influenza detection and treatment, and rationalising isolation facility use; how

55 radiotherapy is often encountered in cancer treatment, and there is a lack of effective treatment.

56 nitiation of pulsed focused ultrasound tumor treatment, and these increases persisted for 3 hours.

57 netics, 17 were unresponsive to all previous treatments, and 32 were receiving a salvage ASCT.

58 Rare cancers pose challenges for diagnosis, treatments, and clinical decision making.

59 These data support development of eCB-based treatment approaches for mood and anxiety disorders and

60 ility and greater decrease in pulsatility on treatment are associated with functional improvement in

61 xidants, appropriate methods of post-harvest treatment are necessary for maintaining these bioactive

62 Cancer treatments are associated with subsequent neoplasms in s

63 After multivariable adjustment, treatment arm independently predicted MI at months 12 to

64 ated with increased risk of bleeding in both treatment arms.

65 mes included symptoms, health status, and AF treatment, as well as 2-year risk of death, hospitalizat

66 Patients and investigators were masked to treatment assignments.

67 d is long-term maintenance of opioid agonist treatment associated with differences in efficacy compar

68 hospital, and mean days of physical therapy treatment associated with hospital length of stay.

69 the possibility of commencing or escalating treatment at an earlier stage.

70 Interestingly, ASO-29 treatment at P1, P5 or P15 resulted in sufficient vestib

71 a therapeutic benefit to balance with ASO-29 treatment at P15 despite the profound vestibular functio

72 ibular functional deficits that persist with treatment at this later time.

73 To date, there is no regenerative treatment available.

74 the proportion of patients who discontinued treatment because of adverse events was low (range, 0%-1

75 All patients received anti-HCV treatment before or after inclusion (with interferon the

76 as not suspected to be related to everolimus treatment, but respiratory failure was suspected to be r

77 the sensitivity of tumor cells to cytotoxic treatments can play an important role in individualized

78 -positive women and those breastfeeding; ART treatments can suppress viral load and are key to preven

79 tively sought care; improving diagnostic and treatment capacity in the formal and informal private se

80 To determine if testosterone treatment compared with placebo is associated with impro

81 Emerging treatment concepts use drugs directed against KIT and ot

82 The Primary Immune Deficiency Treatment Consortium (PIDTC) is enrolling children with

83 emented in eligible US adults, intensive SBP treatment could prevent approximately 107 500 deaths per

84 NAs (DEMs) were identified in the entire TAA-treatment course.

85 13 patients received treatment cycle 2; ten (77%) of the 13 achieved a respon

86 mg/m(2) on days 1, 8, 15, and 22) in 28 day treatment cycles.

87 icator of disease severity and can influence treatment decisions.

88 8%) emissions; nitrification-denitrification treatment decreased NH3 emissions, but increased GHG emi

89 The association between treatment delay and residual symptoms and the lack of im

90 dual symptoms and the lack of improvement in treatment delay during the study period highlight the ne

91 DR was classified according to Early Treatment Diabetic Retinopathy Study Research Group - re

92 results showed that filtration and nuclease treatment did not discernibly increase the sequencing ef

93 f early dermatologic reactions, and cause of treatment discontinuation were annotated.

94 to prasugrel or ticagrelor with an intended treatment duration of 12 months.

95 This treatment effect varied, however, depending on baseline

96 (p=0.051) between type of fractionation and treatment effect, the overall survival benefit being res

97 ful treatment effects, and determine whether treatment effects cumulate over repeated intervention pe

98 No significant treatment effects were observed for duration or severity

99 treatment intensity required for meaningful treatment effects, and determine whether treatment effec

100 aluated according to aggregate measurements, treatment efficacy is generally modest and differences i

101 .75 (95% CI 2545-2759) per QALY gained for a treatment efficacy of 20% and euro4243 per QALY gained f

102 cacy of 20% and euro4243 per QALY gained for treatment efficacy of 50%.

103 suming and labor-intensive, which limits the treatment efficiency especially when the number of sampl

104 nical Question: Are different opioid agonist treatments (eg, methadone vs buprenorphine) associated w

105 rospective cohort, the primary outcomes were treatment failure and adverse events 14 days after diagn

106 us 71 (18%) who received placebo experienced treatment failure or disease recurrence, or died (absolu

107 Time to treatment failure was longer with bevacizumab than with

108 ti-HBs) titres above 10 mIU/mL at the end of treatment (five had maximum anti-HBs concentrations of 7

109 Achieving one-stop diagnosis and treatment for all people with TB will require simpler, m

110 nderstand the effectiveness of screening and treatment for celiac disease, accuracy of screening test

111 are the most widely prescribed pharmacologic treatment for osteoporosis and reduce fracture risk in p

112 Valproic acid (VPA) is a proposed treatment for RP and other neurodegenerative disorders,

113 ho were scheduled for enucleation as primary treatment for uveal melanoma.

114 These findings suggest an effective treatment for vomiting in positive FPIES OFCs and allow

115 Effective drug treatments for many psychiatric diseases are lacking, an

116 ion antidepressants (SGAs) versus most other treatments for this disorder.

117 Seven days after treatment, gametocyte density was significantly reduced

118 Routine aggregate data suggest a large treatment gap (pre-treatment loss to follow-up) between

119 ted, and the projected number of unnecessary treatments generated per TB death averted, if standard X

120 e projected number of additional unnecessary treatments generated, the projected number of TB deaths

121 e medication, and prevalence of BP above the treatment goal among U.S. adults using criteria from the

122 ects between self-reported health status and treatment goal and certain coping strategies.

123 nts were enrolled and randomly assigned to a treatment group (317 to doxorubicin plus evofosfamide an

124 in the untreated group compared with either treatment group (PrOD, 0.3%; LDV/SOF, 1.4%; untreated co

125 est was used to assess for differences among treatment groups for the mouse studies.

126 o difference in overall survival between the treatment groups.

127 n expression between placebo and R-ketorolac treatment groups.

128 PV were prospectively randomized into 1 of 2 treatment groups: Group A received IVB (2.5 mg/0.1 mL) 1

129 RATIONALE: The development of evidence-based treatment guidelines for pediatric pulmonary arterial hy

130 Both treatments had neutral effects on glucose metabolism par

131 higher odds of the primary outcome, whereas treatment in a facility with an observation unit and pre

132 ves the proportion of patients responding to treatment in advanced gastric cancer.

133 y that act directly on brain function and/or treatment in early-stage psychosis populations are neede

134 eduction of macrophages following infliximab treatment in hTNF-Tg mice.

135 y administered immediately after delayed tPA treatment in ischaemic mice, haemorrhagic transformation

136 Short-term IL-33 treatment in mice led to sustained expansion of IL-33 re

137 The positive effects of chronic steroid treatment in muscular dystrophy are paradoxical because

138 after cessation of nucleos(t)ide analog (NA) treatment in patients with chronic hepatitis B (CHB).

139 s using RNA-seq and amino acid levels with N treatment in tea (Camellia sinensis), the most popular b

140 gy offers many possibilities to improve drug treatments, including with regard to drug pharmacology.

141 In addition, linagliptin treatment increased the relative GLP-1 vs glucagon produ

142 GNRH treatment induced c-FOS to replace JDP2 as a c-JUN bindi

143 d in multiple recent studies to find unique, treatment induced mutations in sets of isogenic samples

144 Remission rates within 12 weeks after treatment initiation were significantly higher in the bl

145 Future studies should examine the minimum treatment intensity required for meaningful treatment ef

146 orms better in a simulated non-compliance or treatment interruption scenario.

147 The treatments involve the insertion of fine needles at acup

148 However, the role of PET during treatment (iPET) in daily practice remains a matter of s

149 velop into a lymphoma for which no effective treatment is available.

150 Antifungal treatment is indicated in almost all patients with chron

151 ealth care settings, where adherence to drug treatment is unsupervised and therefore may be suboptima

152 costeroids who required surgery, mepolizumab treatment led to a greater reduction in the need for sur

153 Randomized trials evaluating treatment levels significantly above 90 mm Hg are needed

154 gate data suggest a large treatment gap (pre-treatment loss to follow-up) between the numbers of pati

155 r for the R-E group than for the NR-E group (treatment main effect: F1,68 = 5.4, P = .02, d = 0.50, a

156 Both treatments maintained a good biocompatibility of surface

157 documentation of compliance, and analyses of treatment mediators that will facilitate further therape

158 sented, but do not include modern endoscopic treatment modalities.

159 a group of SDIs during methadone maintenance treatment (n = 23) with a control group (n = 24) in a me

160 METHOD: Adults aged 18-65 with treatment-naive major depression were randomly assigned

161 DOX treatment not only increases interleukin (IL)-33 release

162 not significantly associated with time from treatment, number of calcifications, or sex.

163 mpared with Vaseline plus 5-FU for the field treatment of actinic keratosis in a randomized, double-b

164 r-containing regimens without interferon for treatment of acute HCV in HIV-1 infected individuals (SW

165 2 weeks of sofosbuvir plus ribavirin for the treatment of acute HCV infection in participants with ch

166 itled "Nonpharmacologic Versus Pharmacologic Treatment of Adult Patients with Major Depressive Disord

167 on and is implicated in the pathogenesis and treatment of affective disorders.

168 has been the hallmark anti-CD20 mAb for the treatment of B cell neoplasms, including B cell chronic

169 The treatment of cells with pharmacological inhibitors, such

170 ess and cGVHD, and aimed to create effective treatment of cGVHD.

171 inase 1 (CpCDPK1) are leading candidates for treatment of cryptosporidiosis-associated diarrhea.

172 ly, these findings suggest that the combined treatment of curcumin and essential turmeric oils provid

173 l therapeutic targets for the prevention and treatment of diabetes.

174 it time and was lower in patients with Early Treatment of Diabetic Retinopathy Study (ETDRS) level 20

175 apelinergic system is a promising target for treatment of disease, but this remains to be realized du

176 indings may be relevant to the aetiology and treatment of diverse neurological and psychiatric diseas

177 ynamin ligands, which could be useful in the treatment of dynamin-related disorders.

178 ide critical preclinical evidence supporting treatment of epilepsy and autistic-like behaviors linked

179 d 17beta-HSD1 are attractive targets for the treatment of estrogen-dependent diseases like endometrio

180 hat SFN has potential for the prevention and treatment of HCC.

181 ee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7).

182 harmacological point of intervention for the treatment of Huntington's disease, and potentially for o

183 This review discusses the diagnosis and treatment of hyponatremia, comparing the two guidelines

184 osphate (S1P) receptor (S1PR) agonism in the treatment of infectious diseases.

185 Medical treatment of levodopa-induced dyskinesia (LID) in Parkin

186 highly relevant for the future diagnosis and treatment of meningioma.

187 system represents a potential target for the treatment of metabolic diseases and has been extensively

188 andidate therapeutics that could improve the treatment of metastatic neuroblastoma.

189 m (ENS) might serve as a source of cells for treatment of neurogastrointestinal disorders.

190 and offers a new therapeutic target for the treatment of opioid use disorder.

191 d to be effective and well tolerated for the treatment of patients with ocular hypertension and open-

192 rum longus tendon is frequently used for the treatment of posterior tibial tendon insufficiency or ch

193 -based hSef-b gene delivery approach for the treatment of prostate cancer tumors, and possibly other

194 his multifunctional vaccine approach for the treatment of synucleinopathies, such as Parkinson's dise

195 ohepatitis (NASH) and a promising target for treatment of the condition.

196 onchial circulation, in association with the treatment of the underlying disease, represents a valid

197 are highly promising drug candidates for the treatment of Type 2 diabetes mellitus (T2DM).

198 apies (ACTs) are the mainstay of the current treatment of uncomplicated Plasmodium falciparum malaria

199 pharmacological properties effective in the treatment of various ailments including hepatitis.

200 otection supporting its potential use in the treatment of vascular cognitive impairment.

201 Treatment of WAP-Int3 tumor bearing mice with an IKK inh

202 r level H2O2 during just 1 min of direct CAP treatment on these cells.

203 This safe and effective approach expands treatment options and should be considered as a non-phar

204 To help physicians choose among available treatment options, the American College of Physicians re

205 information, patient pathology, and patient treatment options.

206 or repurpose existing compounds and expedite treatment options.

207 Exclusion criteria were neoadjuvant treatment or pancreatitis as only diagnosis.

208 n between younger age and risk of definitive treatment or risk of biochemical recurrence after delaye

209 t patients and healthy controls and assessed treatment outcome in patients.

210 ately facilitate a more predictable, optimal treatment outcome.

211 risk factors typically associated with poor treatment outcomes.

212 icantly higher serum vitamin D3 levels after treatment (P = 0.007) demonstrated increased skin expres

213 ograms of samples demonstrated the effect of treatment parameters on composition of LWE proteins.

214 In the 4-week post-treatment period, ascending dose cohorts underwent a fur

215 onnaire before the scan (Q1) to indicate the treatment plan without PET/CT information, one immediate

216 should be carefully considered when making a treatment plan.

217 istances from two major municipal wastewater treatment plants (MWWTPs) (Waterloo, Kitchener), includi

218 Thermal treatment preserves the microbiological safety of milk,

219 pretation of results from in situ continuous treatment processes.

220 rmal drying (TD), or lime stabilization (LS) treatment processes.

221 After an Initial Schizophrenia Episode-Early Treatment Program (RAISE-ETP) study, a 34-site cluster-r

222 iated with CTE and for developing preventive treatment programs.

223 ntensive BP-lowering or standard BP-lowering treatment protocols.

224 ch included the cost of the test, subsequent treatments received, and health care encounters, was det

225 Our findings indicate that SS31 treatment reduces Abeta production, reduces mitochondria

226 effective in inducing disease regression in treatment-refractory breast cancer chest wall metastases

227 ciated with death, and one patient died from treatment-related adverse events (myositis in addition t

228 17 (5%) of 370 patients died from non-treatment-related adverse events associated with death,

229 Treatment-related adverse events were generally grade 1

230 ) of 83 patients discontinued therapy due to treatment-related toxicity.

231 logical origin of this pain (critical to its treatment) remains unknown, although spastic motor dysfu

232 ), which contributes to tumor initiation and treatment resistance.

233 for depression and anxiety in traditionally treatment-resistant groups, including AN.

234 Treatment response and recurrence were analyzed with uni

235 We propose a treatment response model, fully parameterized with exper

236 nd validated multiple TFs influencing asthma treatment response.

237 and evaluating preclinical disease-modifying treatment response.

238 group to identify whether they had different treatment responses from the pooled group.

239 This treatment resulted in an increase in the number of blood

240 Continuation of omalizumab after long-term treatment results in continued benefit, as evidenced by

241 itating induction to XR-NTX and on improving treatment retention for both medications.

242 (eNos) KO mouse models of diabetes, TEPP-46 treatment reversed metabolic abnormalities, mitochondria

243 f their gastrointestinal symptoms as well as treatment safety and tolerability.

244 eristics of subpopulations resistant to this treatment.Significance: Illustrating the challenge in tr

245 scovery of new biomarkers and development of treatment solutions to benefit patients with breast canc

246 Treatment-specific changes were observed only during cog

247 Treatment strategies for these diseases have often targe

248 ce that LDR is a promising option for future treatment strategies to prevent cancer metastasis in bre

249 as well as potential future prophylactic and treatment strategies.

250 he cost-effectiveness of a PCSK9i and statin treatment strategy compared with a statin alone strategy

251 ition of HIFs might represent a new powerful treatment strategy.

252 l deterioration using meropenem monotherapy, treatment success was achieved after commencement of fos

253 Treatment success was defined as a 50% or greater reduct

254 of 0 to 2 (</=50% hair loss) was defined as treatment success.

255 Current treatments, such as selective serotonin reuptake inhibit

256 ssions from agricultural soils or wastewater treatment systems.

257 Various treatment technologies have been implemented to reduce e

258 ion of filariasis requires a macrofilaricide treatment that can be delivered within a 7-day period.

259 An urgent need exists for adjuvant treatments that can enhance or replace current therapeut

260 oxygen generation to enhance the efficacy of treatments that depend on the presence of oxygen to elic

261 in knowledge and advances in prevention and treatment, there remain many questions about this declin

262 Despite development of improved treatments, these conditions are associated with high ec

263 ary exacerbation rate in patients continuing treatment through extension week 96 (0.65, 0.56 to 0.75)

264 rapidly than the standard regimen and reduce treatment time to relapse-free cure by 75%.

265 IFN-gamma treatment to GCSCs induced ZEB1 expression, attenuating

266 It then is important to monitor responses to treatment, to quickly identify those therapies that are

267 transplant DAA treatment versus deferred DAA treatment using a cost-effectiveness decision analysis m

268 We compared pretransplant DAA treatment versus deferred DAA treatment using a cost-eff

269 Furthermore, treatment was associated with more unbalanced tumour phy

270 hout telescopic plugged catheter, antibiotic treatment was continued for 7 days.

271 core matching, and by inverse probability-of-treatment weighting.

272 ason pattern 3) who had received no previous treatment were randomly assigned (1:1) to vascular-targe

273 that the Sokal risk score and duration of IM treatment were significantly associated with the probabi

274 When the two treatments were combined, the current increased 12-fold,

275 Age and lack of past alcoholism treatments were independently associated with complete a

276 concentrations of 7681-86 532 mIU/mL during treatment), which were maintained at the end of 1 year f

277 Treatment with a Syk inhibitor significantly reduced ren

278 Treatment with an Aha1 inhibitor, KU-177, dramatically r

279 Treatment with an antimalarial medication reduced parasi

280 at baseline and at 1, 2, and 4 months after treatment with DEX implants.

281 Combined treatment with DHA and Physcion activates AMP-activated

282 transcriptional regulation of SNCA following treatment with different drugs known to regulate alpha-S

283 to up-regulate IFN-beta and TNF-alpha after treatment with DMXAA or the natural STING ligand cyclic

284 ssigned with equal likelihood to 12 weeks of treatment with escitalopram (10-20 mg/day), duloxetine (

285 n-KO pups, the genetic deletion of Slc6a4 or treatment with Fluoxetine, a 5-HT reuptake inhibitor, re

286 However, the ideal duration of treatment with interferon-free regimens, particularly in

287 trollable movements known as dyskinesia upon treatment with L-DOPA.

288 Assessments also gathered information on treatment with medications and confounding factors, such

289 cquiring mutations in response to vaccine or treatment with one or a cocktail of monoclonal antibodie

290 ast cancer were randomly assigned to receive treatment with perindopril, bisoprolol, or placebo (1:1:

291 ot have a sustained virologic response after treatment with regimens containing direct-acting antivir

292 Treatment with Ro 61-8048 decreased nicotine self-admini

293 tudy was to examine the associations between treatment with statins, renin-angiotensin system blocker

294 helix peptide, the present study showed that treatment with the Kalpha2 peptide fused with the TAT pe

295 We have shown that treatment with the KATP channel agonist pinacidil increa

296 cation following infection with FHV, whereas treatment with the KATP channel antagonist tolbutamide d

297 Systemic and ocular treatment with the TR antagonists NH-3 and 1-850 increas

298 x and more extensive MVO than non-QW despite treatment within 12 hours after symptom onset.

299 rently seen in a typical adult with standard treatment, without exceeding the concentration range obs

300 uticals, present in discharges of wastewater treatment works (WwTWs) effluents.

301 erted into the prostate to cover the desired treatment zone and subsequent activation by laser light